Webinars

Upcoming Webinars


Human NerveSim®: A 3D In Vitro Nerve-on-a-Chip Model for Preclinical Drug Screening Featured Image

Human NerveSim®: A 3D In Vitro Nerve-on-a-Chip Model for Preclinical Drug Screening

Webinar Date: December 13, 2022 12:00 pm

Speaker: Megan Terral, Scientific Projects Manager, AxoSim

Preclinical animal models are historically expensive and low-throughput, and have largely failed to deliver results that translate to success in the human system. Peripheral nerves, in particular, lack predictive human-relevant in vitro drug screening models, with less than 7% of neurological drug candidates reaching the marketplace.

AxoSim has developed an all-human NerveSim® micro-physiological platform, using human iPSC-derived sensory neurons and primary human Schwann cells. This platform has been shown to exhibit crucial aspects of PN physiology and function, displaying robust neurite outgrowth, with axonal myelination and measurable electrical activity, acting as a promising screening platform for improving pre-clinical success.

About Megan

Megan is currently focused on demyelination and neuropathy studies at AxoSim. She received an undergraduate degree in biochemical engineering from the University of Georgia, where she grew interested in tissue engineering, biomaterials, and translational research.

*All times zones are Eastern Time*

 

Sign Up

Past Webinars


“Human DRG studies on ectopic spontaneous activity” with Dr. Pat Dougherty of MD Anderson Featured Image

“Human DRG studies on ectopic spontaneous activity” with Dr. Pat Dougherty of MD Anderson

Speaker:  Patrick M Dougherty, Professor of Pain Medicine | MD Anderson Cancer Center

Take an in-depth look at Dr. Dougherty’s innovative research into neuropathic pain experienced by cancer patients.

For 22 years, Dr. Dougherty has held appointment as Professor of Pain Medicine at the University of Texas M.D. Anderson Cancer Center. His recent work centers on determining the mechanisms of neuropathic pain experienced by cancer patients. The work has been composed of parallel studies conducted in both humans and animals. In the human studies, he and his team have conducted psychophysical studies to define the sensory fibers involved in these pain conditions; and more recently, expanded this work to utilize human dorsal root ganglia tissue excised during surgical treatment for cancer. The animal studies have been to define both the peripheral and central neurophysiological mechanisms that are altered following cancer and cancer chemotherapy and to determine agents that may provide a neuroprotective role. The current emphasis in each of these studies is to determine the role that innate immune mechanisms play in the pathogenesis of cancer- and cancer treatment-evoked neuropathic pain.

*All times are Eastern Time Zone

View Webinar
Scaling Peripheral Nerves: A Case Study on CIPN Featured Image

Scaling Peripheral Nerves: A Case Study on CIPN

Speaker:  J. Lowry Curley, PhD, Co-Founder and CEO of AxoSim

Take an in-depth look at AxoSim’s case study on chemotherapeutic drug induced peripheral neuropathy and how this research is leading to the development of AxoSim’s NerveSim® 2.0 platform.

AxoSim assessed NerveSim’s ability to screen for implications of functional and structural nerve dysfunction in chemotherapy-induced peripheral neuropathy. First, this research demonstrates that NerveSim accurately recreates axonal growth, orientation, and function analogous to mature nerve anatomy. By screening known neurotoxic compounds, AxoSim established the potential for its model to prove not only whether a drug is toxic, but to also provide insights into the mechanism of that toxicity. It’s the first 3D in vitro model to collect electrophysiological and histomorphic metrics to assess in vivo pathophysiology.

*All times are Eastern Time Zone

View Webinar
Translating Neurological Stem Cell Research into Therapies for Today’s Patients Featured Image

Translating Neurological Stem Cell Research into Therapies for Today’s Patients

Speaker: Thomas Hartung, MD, PhD, Consulting VP of Scientific Affairs at AxoSim and Professor and Chair, Johns Hopkins University

Neurological impairments are usually irreversible because of limited regeneration in the central nervous system. The regenerative capacity of stem cells makes them an attractive candidate for transplantation therapies, with many stem cells showing promise in basic research and preclinical trials.

Learn about how advances in iPSC-derived organoid models recapitulate the “real” brain environment for CNS precision medicine.

View Webinar